Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01800032 · ClinicalTrials.gov registry record
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
A clinical trial of Neurofibromatosis 1 and Plexiform Neurofibroma, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01800032 is a study of Neurofibromatosis 1 and Plexiform Neurofibroma that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01800032, a study of Neurofibromatosis 1 and Plexiform Neurofibroma, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN). Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. Subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of NF1.
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina-Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-01-16 |
| Est. Completion | 2019-12-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01800032
The ClinicalTrials.gov registry entry for NCT01800032 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 0 interventions.
NCT01800032 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01800032 about?
NCT01800032 is a clinical study titled "PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)". This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN). Subjects will undergo FDG-P...
What is the current status of trial NCT01800032?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-01-16. Estimated completion is 2019-12-05.
What conditions does trial NCT01800032 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Plexiform Neurofibroma, Optic Glioma.
Who is sponsoring clinical trial NCT01800032?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01800032 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.